Twist Bioscience Corp's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 18/158 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 38.52.In the medium term, the stock price is expected to trend up.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Twist Bioscience Corp's Score
Industry at a Glance
Industry Ranking
18 / 158
Overall Ranking
63 / 4563
Industry
Pharmaceuticals
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
11
analysts
Buy
Current Rating
38.517
Target Price
+19.54%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Twist Bioscience Corp Highlights
StrengthsRisks
Twist Bioscience Corporation is a synthetic biology and genomics company that has developed a deoxyribonucleic acid (DNA) synthesis platform to industrialize the engineering of biology. The Company's platform's core is a proprietary technology that specializes in manufacturing synthetic DNA by writing DNA on a silicon chip. It has applied its technology to manufacture a range of synthetic DNA-based products, including synthetic genes, tools for next generation sequencing (NGS) sample preparation, and antibody libraries for drug discovery and development, all designed to enable its customers to conduct research. Its gene products include multiplexed gene fragments, express genes, clonal genes and gene fragments. The Company also manufactures synthetic ribonucleic acid (RNA) as well as antibody proteins. The Company's synthetic DNA tools are used in fields, such as medicine, agriculture, industrial chemicals and defense. It has minority ownership in Atlas Data Storage, Inc.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 53.63% year-on-year.
Undervalued
The company’s latest PE is -25.45, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 71.88M shares, increasing 1.04% quarter-over-quarter.
Twist Bioscience Corporation is a synthetic biology and genomics company that has developed a deoxyribonucleic acid (DNA) synthesis platform to industrialize the engineering of biology. The Company's platform's core is a proprietary technology that specializes in manufacturing synthetic DNA by writing DNA on a silicon chip. It has applied its technology to manufacture a range of synthetic DNA-based products, including synthetic genes, tools for next generation sequencing (NGS) sample preparation, and antibody libraries for drug discovery and development, all designed to enable its customers to conduct research. Its gene products include multiplexed gene fragments, express genes, clonal genes and gene fragments. The Company also manufactures synthetic ribonucleic acid (RNA) as well as antibody proteins. The Company's synthetic DNA tools are used in fields, such as medicine, agriculture, industrial chemicals and defense. It has minority ownership in Atlas Data Storage, Inc.
Ticker SymbolTWST
CompanyTwist Bioscience Corp
CEOLeproust (Emily M)
Websitehttps://www.twistbioscience.com/
FAQs
What is the current price of Twist Bioscience Corp (TWST)?
The current price of Twist Bioscience Corp (TWST) is 33.050.
What is the symbol of Twist Bioscience Corp?
The ticker symbol of Twist Bioscience Corp is TWST.
What is the 52-week high of Twist Bioscience Corp?
The 52-week high of Twist Bioscience Corp is 55.333.
What is the 52-week low of Twist Bioscience Corp?
The 52-week low of Twist Bioscience Corp is 23.300.
What is the market capitalization of Twist Bioscience Corp?
The market capitalization of Twist Bioscience Corp is 2.00B.
What is the net income of Twist Bioscience Corp?
The net income of Twist Bioscience Corp is -77.67M.
Is Twist Bioscience Corp (TWST) currently rated as Buy, Hold, or Sell?
According to analysts, Twist Bioscience Corp (TWST) has an overall rating of Buy, with a price target of 38.517.
What is the Earnings Per Share (EPS TTM) of Twist Bioscience Corp (TWST)?
The Earnings Per Share (EPS TTM) of Twist Bioscience Corp (TWST) is -1.299.